Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 7/20 | 0.36 |
| ▸ | CCNK | O75909 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945923 | 0.93 | MAPT (0.42) | FYNMAPTTP53SMN1; SMN2F2RL3 | |
| SCHEMBL1946451 | 0.85 | FYN (0.47) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1651387 | 0.82 | FYN (0.56) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1946366 | 0.82 | FYN (0.53) | FYNMAPTTP53SMN1; SMN2TTK | |
| SCHEMBL1945189 | 0.82 | FYN (0.68) | FYNMAPTCCNKCDK9F2RL3 | |
| SCHEMBL1945164 | 0.82 | FYN (0.46) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1945560 | 0.81 | MAPT (0.49) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1945954 | 0.81 | FYN (0.56) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1945884 | 0.81 | FYN (0.45) | FYNPIK3CDPI4KAPIK3CGPI4KB | |
| SCHEMBL1944445 | 0.81 | FYN (0.47) | FYNPIK3CDPI4KAPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885PIK3CD 741/4885PI4KA 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.